Supratherapeutic Response to Ezetimibe in a Statin Intolerant Patient

A 56-year-old white man with hypertension and a strong family history of cardiovascular disease was referred to a lipid-specialty clinic secondary to a statin intolerance (ie, myalgias) and dyslipidemia. The patient was initiated on ezetimibe 10 mg daily and experienced a supratherapeutic response. His baseline low-density lipoprotein cholesterol was reduced by 52% after 8 months of ezetimibe therapy, with no other explanation for the marked reduction. Recent studies have indicated a wide range of response to ezetimibe with different genetic variations. It is likely that this patient has a genetic variation that resulted in a hyperresponse to ezetimibe.

[1]  R. Fresa,et al.  Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. , 2007, Atherosclerosis.

[2]  J. Mckenney,et al.  Role of Prescription Omega‐3 Fatty Acids in the Treatment of Hypertriglyceridemia , 2007, Pharmacotherapy.

[3]  B. Hawes,et al.  In Vivo Responsiveness to Ezetimibe Correlates with Niemann-Pick C1 Like-1 (NPC1L1) Binding Affinity: Comparison of Multiple Species NPC1L1 Orthologs , 2007, Molecular Pharmacology.

[4]  E. Schadt,et al.  Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. , 2005, Genomics.

[5]  S. Koshman,et al.  Supratherapeutic Response to Ezetimibe Administered with Cyclosporine , 2005, The Annals of pharmacotherapy.

[6]  P. McBride,et al.  A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. , 2005, Mayo Clinic proceedings.

[7]  P. Ziajka,et al.  Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe. , 2004, The American journal of cardiology.

[8]  E. Nutescu,et al.  Ezetimibe: A Selective Cholesterol Absorption Inhibitor , 2003, Pharmacotherapy.

[9]  V. F. Mauro,et al.  Ezetimibe for Management of Hypercholesterolemia , 2003, The Annals of pharmacotherapy.

[10]  D. Tribble,et al.  Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans , 2002, Circulation.